IDEXX Laboratories, Inc.'s next confirmed earnings release is scheduled for February 8, 2027.
| Earnings Date | 2/8/2027 |
As of September 30, 2026, IDEXX Laboratories, Inc. has 78.79M shares outstanding.
| Shares Outstanding | 78.79M |
As of September 30, 2026, IDEXX Laboratories, Inc. maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.05, indicating elevated leverage, while an interest coverage ratio of 48.11 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.19 |
| Quick Ratio | 0.73 |
| Debt / Equity | 52.05 |
| Debt / EBITDA | 0.58 |
| Interest Coverage | 48.11 |
Over the twelve months ended September 30, 2026, IDEXX Laboratories, Inc. posted a return on equity (ROE) of 68.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 42.49 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 33.33, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 43.86, useful for judging operating efficiency across full business cycles. The company generates approximately 353,604.03 in revenue per employee across its workforce of 11,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.44 indicates how many times IDEXX Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 68.93 |
| Return on Assets (ROA) | 33.33 |
| Return on Invested Capital (ROIC) | 42.49 |
| Return on Capital Employed (ROCE) | 43.86 |
| Revenue Per Employee | 353,604.03 |
| Employee Count | 11,000.00 |
| Inventory Turnover | 4.44 |
Over the twelve months ended September 30, 2026, IDEXX Laboratories, Inc. recorded 247.60M in income tax expense. That works out to an effective tax rate of 20.07, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.23B, leaving 986.29M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 247.60M |
| Effective Tax Rate | 20.07 |
As of the close on November 4, 2026, IDEXX Laboratories, Inc.'s stock has gained approximately 54.76% over the past 52 weeks.
| 52-Week Price Change | 54.76% |
Over the twelve months ended September 30, 2026, IDEXX Laboratories, Inc. generated 3.89B in revenue and converted that into 986.29M in net income, yielding earnings per share of 12.37. EBITDA reached 1.39B, while operating income came in at 1.26B.
| Revenue | 3.89B |
| Gross Profit | 2.44B |
| Operating Income | 1.26B |
| Pretax Income | 1.23B |
| Net Income | 986.29M |
| EBITDA | 1.39B |
| EBIT | 1.26B |
| Earnings Per Share (EPS) | 12.37 |
As of September 30, 2026, IDEXX Laboratories, Inc. holds 164.80M in cash and equivalents against 811.73M in total debt, resulting in a net debt position of 543.41M. Total book value stands at 1.56B, with working capital of 196.71M providing operational flexibility.
| Cash & Cash Equivalents | 164.80M |
| Total Debt | 811.73M |
| Net Debt | 543.41M |
| Equity (Book Value) | 1.56B |
| Book Value Per Share | 19.79 |
| Working Capital | 196.71M |
IDEXX Laboratories, Inc. produced 1.18B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -99.19M in capital expenditures, free cash flow totaled 1.08B - equivalent to 13.67 per share.
| Operating Cash Flow | 1.18B |
| Capital Expenditures | -99.19M |
| Free Cash Flow | 1.08B |
| FCF Per Share | 13.67 |
Over the twelve months ended September 30, 2026, IDEXX Laboratories, Inc. posted a gross margin of 62.72, reflecting its pricing power and cost economics. The operating margin of 32.30 and net profit margin of 25.36 provide insight into operational efficiency.
| Gross Margin | 62.72 |
| Operating Margin | 32.30 |
| Pretax Margin | 31.72 |
| Profit Margin | 25.36 |
| EBITDA Margin | 35.69 |
IDEXX Laboratories, Inc.'s most recent stock split took place on June 16, 2015 with a 1:2 split ratio.
| Last Split Date | 6/16/2015 |
| Split Ratio | 1:2 |